CN116041525B - Dcp特异性抗体及其应用 - Google Patents
Dcp特异性抗体及其应用 Download PDFInfo
- Publication number
- CN116041525B CN116041525B CN202211490643.XA CN202211490643A CN116041525B CN 116041525 B CN116041525 B CN 116041525B CN 202211490643 A CN202211490643 A CN 202211490643A CN 116041525 B CN116041525 B CN 116041525B
- Authority
- CN
- China
- Prior art keywords
- seq
- variable region
- antibody
- light chain
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 20
- 210000004027 cell Anatomy 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 5
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000008157 ELISA kit Methods 0.000 claims description 2
- 241000238631 Hexapoda Species 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 abstract 1
- 241000282414 Homo sapiens Species 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 238000002649 immunization Methods 0.000 description 9
- 230000003053 immunization Effects 0.000 description 9
- 238000001514 detection method Methods 0.000 description 8
- 239000000872 buffer Substances 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 238000011534 incubation Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 238000007664 blowing Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 102100027378 Prothrombin Human genes 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 210000000548 hind-foot Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000011895 specific detection Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 241000283707 Capra Species 0.000 description 1
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101000651439 Homo sapiens Prothrombin Proteins 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- 240000000220 Panda oleosa Species 0.000 description 1
- 235000016496 Panda oleosa Nutrition 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 101150054938 dcp gene Proteins 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910001453 nickel ion Inorganic materials 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/974—Thrombin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本申请提供了DCP特异性抗体及其应用。所述DCP特异性抗体的CDR序列为：H‑CDR1为SEQ ID NO.1,H‑CDR2为SEQ ID NO.2,H‑CDR3为GPS,L‑CDR1为SEQ ID NO.4,L‑CDR2为SEQ ID NO.5,L‑CDR3为SEQ ID NO.6；或者，H‑CDR1为SEQ ID NO.7,H‑CDR2为SEQ ID NO.8,H‑CDR3为SEQ ID NO.9,L‑CDR1为SEQ ID NO.10,L‑CDR2为SEQ ID NO.11,L‑CDR3为SEQ ID NO.12。本申请的DCP特异性抗体可用于肿瘤的诊断。
Description
技术领域
本申请属于蛋白领域和生物领域，具体地，本申请提供了DCP特异性抗体及其应用。
背景技术
脱-羧基凝血酶原(DCP)是一种异常的凝血酶原，最早于肝癌患者血清中发现。其单独使用或者与AFP联合使用都是多种肝癌诊断的有效指标。
目前，DCP的抗体，特别是单克隆抗体报道较少；多克隆抗体则容易受到血液中其他凝血酶等成分的非特异性结合影响，在灵敏度和特异性上明显不足。本领域中有研究新型DCP单克隆抗体的需求。
发明内容
针对上述需求，一方面，本申请提供了DCP特异性抗体，所述DCP特异性抗体的CDR序列为：
H-CDR1为SEQ ID NO.1,H-CDR2为SEQ ID NO.2,H-CDR3为GPS,L-CDR1为SEQ IDNO.4,L-CDR2为SEQ ID NO.5,L-CDR3为SEQ ID NO.6；
或者，H-CDR1为SEQ ID NO.7,H-CDR2为SEQ ID NO.8,H-CDR3为SEQ ID NO.9,L-CDR1为SEQ ID NO.10,L-CDR2为SEQ ID NO.11,L-CDR3为SEQ ID NO.12。
进一步地，所述DCP特异性抗体的重链和轻链可变区序列为：
重链可变区：SEQ ID NO.13；轻链可变区：SEQ ID NO.14；
或者，重链可变区：SEQ ID NO.15；轻链可变区：SEQ ID NO.16。
进一步地，所述DCP特异性抗体的重链和轻链序列为：
重链：SEQ ID NO.17，轻链：SEQ ID NO.18；
或者，重链：SEQ ID NO.19，轻链：SEQ ID NO.20。
另一方面，本申请提供了上述抗体的制备方法，包括在宿主中表达编码上述抗体的基因。
进一步地，在宿主中表达编码重链可变区和轻链可变区的基因SEQ ID NO.21和SEQ ID NO.22；
或者，在宿主中表达编码重链可变区和轻链可变区的基因SEQ ID NO.23和SEQ IDNO.24。
进一步地，在宿主中表达编码重链和轻链的基因SEQ ID NO.25和SEQ ID NO.26；
或者，在宿主中表达编码重链和轻链的基因SEQ ID NO.27和SEQ ID NO.28。
进一步地，所述宿主选自哺乳动物细胞、细菌、酵母或者昆虫细胞。
另一方面，本申请提供了上述DCP特异性抗体在制备检测肿瘤的试剂盒中的应用。
进一步地，所述肿瘤为肝癌。
进一步地，上述试剂盒为ELISA试剂盒。
附图说明
图1为抗体1-6H-2的特异性检测结果；
图2为抗体6-11C-2的特异性检测结果；
图3为抗体灵敏度检测结果。
具体实施方式
实施例1抗体的制备和测序
1在大肠杆菌中表达DCP蛋白
检索现有技术中的相关序列，最后选择DCP基因和蛋白序列(NM_000506.5Homosapiens coagulation factor II,thrombin(F2),mRNA；NP_000497.1prothrombinpreproprotein[Homo sapiens])。
委托苏州金唯智公司合成表达载体：质粒：pET-28a(+)、5’酶切位点：BamHI、3’酶切位点：Xhol、表达菌株：BL21(DE3)。
取100ng质粒和20ul感受态细胞混合，冰上放置30min；热激45s，冰上放置2min，37℃，200rpm培养1h，2000rpm离心，Kana抗性平板筛选。37℃培养箱过夜培养。
第二天挑菌扩大培养，1mM IPTG诱导，37℃诱导5h，SDS-PAGE检测诱导效果，观察到预期条带显示表达成功。
表达成功后增加摇菌体积，进行蛋白纯化。
2小鼠免疫过程
第一次免疫：重组人DCP蛋白(PBS缓冲液，浓度为2mg/ml)100ug和完全弗氏佐剂按照体积比1：1完全混合后，小鼠后足垫皮下注射。
第二次免疫：第一次免疫完成后2周进行第二次免疫，重组人DCP蛋白(PBS缓冲液，浓度为2mg/ml)100ug和不完全弗氏佐剂按照体积比1：1完全混合后，小鼠后足垫皮下注射。
第三次免疫：第二次免疫完成后2周进行第三次免疫，重组人DCP蛋白(PBS缓冲液，浓度为2mg/ml)100ug和PBS缓冲液按照体积比1：1混匀后，腹腔注射。
第三次免疫完成后10天取小鼠眼周血做效价检测。
加强免疫：融合前三天，重组人DCP蛋白(PBS缓冲液，浓度为2mg/ml)100ug和PBS缓冲液按照体积比1:1混匀后，小鼠尾静脉注射。
3细胞融合
得到小鼠脾脏细胞和骨髓瘤细胞后，RPMI-1640培养基各清洗2次，然后按照数量比1:5混合骨髓瘤细胞和淋巴细胞，得到细胞混合物；将所述细胞混合物放到50ml离心管中，用RPMI-1640基础培养基40ml重悬，然后在1000rpm条件下离心5min，弃上清，摇动离心管使细胞均匀，缓慢加入1ml50％PEG，反应90秒，然后加入10mlRPMI-1640培养基终止PEG，把融合的细胞放到37℃水浴锅中反应10min，在1000rpm条件下离心5min，弃上清后加入HATRPMI-1640完全培养基重悬细胞。
融合的细胞辅到96孔板中，每孔100μl；然后将细胞培养板放到CO2培养箱中培养，融合10天后，取细胞培养上清，ELISA检测阳性孔后做半固体培养挑单克隆。
4单克隆抗体的获得和测序
吹打阳性孔中细胞，取10ul计数为N，根据有限稀释法在离心管中加入PBS缓冲液，取100μl细胞悬液到离心管中，吹匀后取30ul，加入500ulRPMI-1640完全培养基，吹匀后接种到半固体培养基上，6-8天后挑选肉眼可见的单克隆细胞株接种到96孔板上，然后筛选出阳性单克隆细胞株。
对腹水进行纯化处理的操作具体如下：
将蛋白质A琼脂糖凝胶介质装入镍离子亲和层析柱，将腹水与PBS按照体积比1:1等量混合后缓慢上样，待抗体结合后用甘氨酸洗脱缓冲液洗脱，即得本申请DCP单克隆抗体。委托百英生物公司进行抗体测序。
实施例2抗体的特异性和灵敏度检测
特异性：
Elisa检测两个抗体的特异性，抗原为重组人全长DCP蛋白，铺板浓度梯度设置为2ug/ml(不加人血清的阳性对照)，2ug/ml，1ug/ml，0.2ug/ml，0.04ug/ml，0.008ug/ml，0。
将1-6H-2和6-11C-2单克隆细胞培养上清和人血清1:1混合均匀后孵育0.5h，加入酶标板37℃继续孵育1h，每孔上样量为100ul。
二抗为标记HRP的羊抗鼠，孵育0.5h后加TMB显色。
从图1、2结果来看，加入人血清后抗体效价没有明显降低，且与抗原浓度成正相关，说明人血清中没有抗体非特异识别的物质来影响检测，抗体特异性较好。
灵敏度：
夹心法Elisa检测抗体识别重组人DCP蛋白的灵敏度，其中1-6H-2为捕获抗体无标记，6-11C-2为检测抗体，标记HRP。
将捕获抗体1-6H-2包被到酶标板中，然后加入10倍梯度稀释的重组人DCP蛋白，37℃孵育1h后加入检测抗体6-11C-2，继续孵育1h后加入TMB显色。
从图3结果来看，1-6H-2和6-11C-2用传统夹心ELisa检测抗原的灵敏度可以达到2ng/ml左右。
Claims (7)
1.特异性结合DCP的抗体，其特征在于，所述抗体包含重链和轻链；
重链包含3个CDR，重链CDR序列为：
H-CDR1：SEQ ID NO.1, H-CDR2：SEQ ID NO.2, H-CDR3：SEQ ID NO.3；
轻链包含3个CDR，轻链CDR序列为：
L-CDR1：SEQ ID NO.4, L-CDR2：SEQ ID NO.5, L-CDR3：SEQ ID NO.6；
或者，
重链包含3个CDR，重链CDR序列为：
H-CDR1：SEQ ID NO.7, H-CDR2：SEQ ID NO.8, H-CDR3：SEQ ID NO.9；
轻链包含3个CDR，轻链CDR序列为：
L-CDR1：SEQ ID NO.10, L-CDR2：SEQ ID NO.11, L-CDR3：SEQ ID NO.12。
2.权利要求1所述的抗体，其特征在于，所述抗体的重链和轻链可变区序列为：
重链可变区：SEQ ID NO.13；轻链可变区：SEQ ID NO.14；
或者，重链可变区：SEQ ID NO.15；轻链可变区：SEQ ID NO.16。
3.权利要求1或2所述的抗体的制备方法，其特征在于，所述制备方法包括在宿主中表达编码权利要求1或2所述的抗体的基因。
4. 权利要求3所述的制备方法，其特征在于，所述制备方法中在宿主中表达编码重链可变区和轻链可变区的基因SEQ ID NO.21和SEQ ID NO.22；
或者，在宿主中表达编码重链可变区和轻链可变区的基因SEQ ID NO.23和SEQ IDNO.24。
5.权利要求3或4所述的制备方法，其特征在于，其中所述宿主选自哺乳动物细胞、细菌、酵母或者昆虫细胞。
6.权利要求1或2所述的抗体在制备检测肿瘤的试剂盒中的应用，其中所述肿瘤为肝癌。
7.权利要求6所述的应用，其特征在于，所述试剂盒为ELISA试剂盒。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211490643.XA CN116041525B (zh) | 2022-11-25 | 2022-11-25 | Dcp特异性抗体及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211490643.XA CN116041525B (zh) | 2022-11-25 | 2022-11-25 | Dcp特异性抗体及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116041525A CN116041525A (zh) | 2023-05-02 |
| CN116041525B true CN116041525B (zh) | 2023-06-23 |
Family
ID=86122596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211490643.XA Active CN116041525B (zh) | 2022-11-25 | 2022-11-25 | Dcp特异性抗体及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116041525B (zh) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112592408A (zh) * | 2020-07-20 | 2021-04-02 | 北京鼎成肽源生物技术有限公司 | 一种靶向c-Met的单链抗体、嵌合抗原受体、重组载体、CAR-T细胞及应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020000386A2 (pt) * | 2017-07-13 | 2020-07-21 | F. Hoffmann-La Roche Ag | agente de ligação específico, anticorpo monoclonal, métodos de detecção de pivka-ii, método diagnóstico do carcinoma hepatocelular, uso de um agente de ligação específico e kit |
-
2022
- 2022-11-25 CN CN202211490643.XA patent/CN116041525B/zh active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112592408A (zh) * | 2020-07-20 | 2021-04-02 | 北京鼎成肽源生物技术有限公司 | 一种靶向c-Met的单链抗体、嵌合抗原受体、重组载体、CAR-T细胞及应用 |
Non-Patent Citations (3)
| Title |
|---|
| Epitope characterization of an anti-PIVKA-II antibody and evaluation of a fully automated chemiluminescent immunoassay for PIVKA-II;Hideki Kinukawa 等;Clinical Biochemistry;第48卷;第1120-1125页 * |
| 人 Dcp2基因克隆表达、多克隆抗体的制备及其应用;刘利新 等;中国科学院研究生院学报;第24卷(第3期);第362-367页 * |
| 异常凝血酶 DCP 基因克隆表达、纯化及单克隆抗体制备与鉴定;沈鹏 等;世界华人消化杂志;第21卷(第35期);第3932-3939页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116041525A (zh) | 2023-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110616192B (zh) | 一种抗人神经丝轻链(nefl)的单克隆抗体及其应用 | |
| CN116396384B (zh) | 针对小鼠脂联素的兔单克隆抗体及其应用和双抗夹心法酶联免疫检测试剂盒 | |
| CN116199783B (zh) | Alp单克隆抗体及其应用 | |
| WO2016002189A1 (ja) | 抗プログルカゴン抗体 | |
| CN116355091A (zh) | 一种抗人神经丝轻链的单克隆抗体21d2-30d3及其产品和应用 | |
| CN115286715B (zh) | 一种抗cd3的纳米抗体或其抗原结合部分及其制备方法 | |
| WO2025087317A1 (zh) | 靶向Artemin的抗体及其制备方法和在肿瘤治疗中的应用 | |
| CN118638236B (zh) | 抗人cd127蛋白的抗体、抗体偶联物及其应用 | |
| CN118344476B (zh) | 人c反应蛋白单克隆抗体、抗体对和检测试剂或试剂盒及其应用 | |
| CN116041525B (zh) | Dcp特异性抗体及其应用 | |
| CN103842503A (zh) | 上皮性卵巢癌标志物检测用抗体和上皮性卵巢癌判定方法 | |
| CN116751299A (zh) | 抗CD30ki-1&4抗体及其制备方法及其应用 | |
| CN115850496B (zh) | Fuca1特异性抗体及其应用 | |
| CN111763255B (zh) | 一种经基因修饰的vegfa蛋白及其单克隆抗体与应用 | |
| CN115960237A (zh) | Oxa-48酶单克隆抗体及应用 | |
| CN115894683B (zh) | 检测甲胎蛋白的单克隆抗体及其应用 | |
| CN110054675B (zh) | 免疫原性多肽以及抗ttc36抗体cp4-3及应用 | |
| CN106367395B (zh) | 一种增殖细胞核抗原的单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株 | |
| CN119735675B (zh) | 一种抗gdf15抗体及其制备方法和应用 | |
| CN118561998B (zh) | 抗羊白介素6抗体、抗体对及其应用 | |
| CN117777295B (zh) | 抗人cd44蛋白的兔单克隆抗体及其应用 | |
| CN118440194B (zh) | 用于检测鼠白介素-2的抗体、抗体对及检测试剂或试剂盒 | |
| CN118930648B (zh) | 抗人pax8蛋白的兔单克隆抗体、抗体偶联物及其应用 | |
| CN115825415B (zh) | 阻断剂和体外免疫诊断产品、应用 | |
| CN120647765A (zh) | 抗可溶性转铁蛋白受体单克隆抗体及其制备方法与应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |